#Czech Republic #Ostrava #Stimvia #URIS® #OveractiveBladder

Stimvia's Global Expansion of URIS® Therapy

Stimvia, a Czech-based medical technology company focused on developing non-invasive neuromodulation therapies for overactive bladder (OAB), has recently announced significant steps to bolster its global operations. As part of its expansion strategy, the company is enhancing its Scientific Advisory Board and strengthening its commercial leadership, signaling a pivotal moment for the URIS® therapy, its flagship product.

Strengthening Scientific Credibility

To support its ambitious goals, Stimvia has appointed leading urology experts from the United States, the United Kingdom, and Europe to its Scientific Advisory Board. This move is aimed at reinforcing the company's clinical and scientific leadership as it ventures into international markets.

Joining the Advisory Board are notable figures such as:

• - Dr. David R. Staskin, a Boston-based urologist with worldwide recognition in lower urinary tract disorders, with extensive experience in medical device development and clinical research.
• - Professor Alan J. Wein, MD, PhD, FACS, a prominent authority on overactive bladder and contributor to international treatment guidelines, previously the head of Urology at the University of Pennsylvania.
• - Professor Christopher R. Chapple, a globally recognized expert in functional and reconstructive urology based in the UK.
• - Professor Bertil Blok, a leading specialist in neurourology and functional urology from the Netherlands.

With this high-caliber advisory team, Stimvia aims to facilitate collaborations with top clinical professionals, support evidence generation, and strengthen trust among health sector partners and investors.

Commercial Leadership for Global Growth

In tandem with enhancing its advisory body, Stimvia has taken substantial steps to accelerate its commercial growth on a global scale. The company has onboarded senior commercial talent, notably bringing in Dr. David da Silva, who will spearhead global distribution and market development. Dr. da Silva boasts over ten years of commercial leadership experience in major medical technology firms like Medtronic, Stryker, and Ascendis Health. His focus will be on scalable strategic partnerships and market entry strategies in Europe, Latin America, and other key regions.

Furthermore, Alim Topdag, MSc, has been appointed as the Sales and Business Development Director for markets outside of the United States. He will oversee sales and drive business development in priority territories through partnerships with distributors and direct business models, while also offering support for clinical and technical implementation of URIS® therapy.

By combining expert clinical advice with an expanded commercial leadership team, Stimvia is preparing the foundation for the international adoption of URIS® and its next growth phase in global urology markets.

Looking Ahead

The global healthcare landscape is ever-evolving, and Stimvia is strategically positioning itself to meet the needs of patients with overactive bladder while simultaneously delivering value to investors and partners. As the company moves forward, the introduction of URIS® therapy to new markets exemplifies its commitment to innovation in medical technology and neuromodulation therapies. With a robust foundational strategy, Stimvia is set to redefine standards of care in urology, benefiting countless individuals suffering from OAB worldwide.